COVID-19: Get Vaccinated. Get Tested. Visitor Guidelines. Please use ER for Emergency Issues only.


  • A021502 Combination Chemotherapy with or Without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • A021602    Cabozantinib S-malate in Treating Patients with Neuroendocrine Tumors previously Treated with Everolimus that are locally advanced, metastatic or cannot be removed by surgery
  • A021703 Randomized Double Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
  • A221805 Duloxetine to prevent Oxaliplatin-induced peripheral neuropathy: A Randomized, Double blind placebo controlled phase II study
  • EA2165 Randomized Phase II Study of Nivolumab after combined modality Therapy (CMT) in High Risk Anal Cancer(stage II-IIIB)
  • EA2174 A Phase II/III study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
  • EA2176 A Phase III Study of Immune Checkpoint inhibition with chemotherapy in treatment naive metastatic anal cancer patients
  • EA2182 A Randomized Phase II study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
  • EA2183 A Phase III study of consolidative radiotherapy in patients with Oligometastatic HER2 negative esophageal and gastric adenocarcinoma
  • EA2185 Comparing the clinical impact of pancreatic cyst surveillance programs
  • EA2186  A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients (70 and older) with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
  • EA2187 A Phase 2 Study of Pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma
  • GI005 Phase II/III study of Circulating tumor DNA as a predictive Biomarker in adjuvant chemotherapy in stage IIA colon cancer (COBRA)
  • S0820 Adenoma and Second Primary Prevention Trial
  • S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab compared to Cetuximab and Irinotecan in Advanced/Metastatic Colorectal Cancer with HER2 Amplification
  • S1922 Randomized Phase II Selection Study of Ramucirumab and Paclitaxel vs. FOLFIRI in refractory small bowel adenocarcinoma